anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a formula in powder form, other burn remedies are a cream. Its use is for minor burns. Once the powder is applied to the wet skin it will draw the liquid from the burned skin preventing a blister from forming, speeds up the healing process and removes all pain in 20 minutes. The ingredients are common household items. Water, vinegar, aloe vera, sodium chloride, baking soda and food coloring. For use at home at work or at play.
Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
AVFs are the preferred means of vascular access for maintenance hemodialysis. Nonmaturation occurs in 30-50% of cases, with highest rates in radio-cephalic fistulas. Inflammatory cytokines are involved in this process of nonmaturation. By suppressing inflammation, corticosteroids might promote maturation, but have significant systemic side effects. Liposomal prednisolone has a long circulation time and targets inflamed tissue with low systemic concentrations and limited side effects. In an animal study, it was demonstrated to promote AVF maturation. At present, no drug therapy aimed at improving shunt maturation is available. This study will investigate if liposomal prednisolone is effective in promoting AVF maturation when administered to human subjects after surgical creation of a radio-cephalic AVF.
Classical massage will be applied to the lumbal and abdominal region 5 days a week, from the estimated date of ovulation until the next menstrual bleeding begins. The application will take approximately 15 minutes. During the massage, the physiotherapist will apply stroking and kneading movements by using baby oil. During the treatment of the lumbal region, the patient will be in the prone position; during the treatment of the abdominal region, the patient will be in the supine position.
Recombinant H3N2 (A/Texas/71/2017 (H3N2), clade 3C3a) influenza virus at 106 TCID50 dose. This dose has an attack rate of \>70%, and a good safety profile related to adverse events reporting. Each vial of virus stock and diluent will be individually labeled with the product name, description and caution statement.
Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP\< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
Evidence suggests a link between diabetes-related processes and increased risk of cognitive decline and dementia in older adults. Optimal disease self-management may be key in the prevention of cognitive decline among older diabetic patients, but this may be compromised due to sub-clinical cognitive impairment.

In the current study, 120 community-dwelling, non-demented participants aged 65 and over, with a diagnosis of Type 2 diabetes will be randomly assigned either to an 8-week, home-based individually-tailored CCT program with adaptive difficulty level, and regular performance feedback, or to an 8-week, home-based active control (AC) condition, involving training on a generic CCT program with fixed difficulty level and without performance feedback. Both intervention groups also include a range of theory-informed behavior change techniques (BCTs), including self-efficacy management, self-monitoring and goal-setting in order to enhance treatment fidelity, and to maximize treatment compliance and adherence. In both groups, participants train approx. 30 min. per day, 3 times per-week for 8-weeks. Participants undergo a comprehensive evaluation of all outcomes at baseline, immediately after the intervention, and at a 6-month follow-up, with 1-week booster training completed 3 months from completion of the intervention.
The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
The invention relates to a method for manufacturing a transdermal patch from a drug-containing web that minimizes waste. The web is a layered composite that includes at least a backing layer and a drug-in-adhesive layer and a first strippable release liner. The web is kiss-cut along intersecting cut lines at least down to the depth of the liner, generally defining the extent of individual transdermal patches. The intersections of the cut lines define small zones that are punched out of the web in a generally star shape. The portions of the web above the liner are peeled away from the liner and transferred to a faster moving second liner so that the patches are now further spaced apart from one another. This second liner is then cut to provide transdermal patches that are mounted to release liners that are substantially broader in extent than the patches themselves.
INTRODUCTION: Hirschsprung's disease-associated enterocolitis (HAEC) remains a substantial morbidity and mortality risk in Hirschsprung's disease. HAEC is a challenge. Its p athophysiology is still a mystery, and no adequate treatment strategy exists. The aim of the study is to analyse the pre-and post-operative, mortality and complications: strictures, anastomotic leak, constipation and incontinence associated with HAEC.
MATERIALS AND METHODS: Adjust to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020; this study met all the requirements and was up-todate. The search approach was online publications between 2013 and 2023 in Pubmed and SagePub. It was decided not to consider review pieces that had already been published and half done. The STATA 18th version was used for metaanalysis.
RESULTS: Our search results included 370 PubMed and 149 SagePub articles. Since 2013, 134 PubMed and nine SagePub articles have been obtained, and seven studies have met the criteria.
CONCLUSION: Disorders of intestinal motility in the aganglionic segment and accumulation of faeces disrupt the balanced microbiota population, which are factors of preoperative HAEC. Major congenital anomalies and low birth weight worsen pre-operative HAEC. Pre-operative HAEC can continue and affect the post-operative. Constipation and fecal incontinence are still the main challenges after HSCR surgery.
Sternal wound complications following sternotomy need a multidisciplinary approach in high-risk postoperative cardiac surgical patients. Poorly controlled pain during surgical management of such wounds increases cardiovascular stress and respiratory complications. Multimodal analgesia including intravenous opioids, non-opioid analgesics, and regional anesthesia techniques, like central neuraxial blocks and fascial plane blocks, have been described. Pecto-intercostal fascial plane block (PIFB), a novel technique, has been effectively used in patients undergoing cardiac surgery. Under ultrasound (US) guidance PIFB is performed with the aim of depositing local anesthetic between two superficial muscles, namely the pectoralis major muscle and the external intercostal muscle. The authors report a series of five cases where US-guided bilateral PIFB was used in patients undergoing sternal wound debridement. Patients had excellent analgesia intraoperatively as well as postoperatively for 24 hours with minimal requirement of supplemental analgesia. None of the patients experienced complications due to PIFB administration. The authors concluded that bilateral PIFB can be effectively used as an adjunct to multimodal analgesia with general anesthesia and as a sole anesthesia technique in selected cases of sternal wound debridement.
The invention discloses instant herbal medicine for treating chronic pharyngitis and a preparation method thereof. The instant herbal medicine is prepared from, by weight, 10-20 parts of green plum blossoms, 8-13 parts of green tea, 15-20 parts of Chinese olive, 10-15 parts of honeysuckle, 10-15 parts of chrysanthemum and 10-20 parts of folium isatidis. Multiple natural Chinese herbs capable of clearing away heat and toxic materials, moistening lungs and relieving sore throats are used as raw materials and made into the instant herbal medicine. A patient needs to mix the medicine with boiled water before taking the medicine. The medicine is convenient to carry and take. The instant herbal medicine can treat both primary symptoms and secondary symptoms and is remarkable in chronic pharyngitis treatment effect.
Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.
The National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) is planned to be fielded in 2012 by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in conjunction with Westat, through a contract under data collection authority Title 42 U.S.C. 285 n (Attachment 23.a). The target population of the NESARC-III is the civilian noninstitutionalized population, 18 years and older, residing in the contiguous United States (U.S.) and Alaska and Hawaii. The sample (N=46,500) will include households and selected noninstitutionalized group quarters (e.g., agricultural, vocational training and other dormitories, halfway houses, hostels, YMCAs, shelters, campgrounds, carnivals). The NESARC-III will collect information on alcohol use disorders and related physical and mental disabilities in addition to DNA to be obtained through saliva samples.

This request for IRB approval also includes a pilot test of approximately 50 respondents that will serve the sole purpose of testing the data collection procedures, operations and system architecture of the NESARC-III survey. There will also be two small methodological subcomponents of the NESARC-III proper that will serve the purposes of providing ongoing validation and assessment of the utility of outcome measures appearing on the major data collection questionnaire, the Alcohol Use Disorder and Associated Disabilities Interview Schedule-V (AUDADIS-V: Grant et al., 2008). In the first methodological subcomponent, 1000 respondents participating in the NESARC-III proper will be re-interviewed with a shorter version of the original AUDADIS-V. In the second methodological subcomponent, 700 different respondents participating in the NESARC-III proper will be re-interviewed using a different assessment instrument, the Psychiatric Research Interview for Substance and Mental Disorders (PRISM: Hasin et al., 2008), covering information on major outcome variables very similar to those appearing in the AUDADIS-V. NIAAA has conducted such validation/utility tests that have received OMB approval (OMB No. 0930-0151, OMB No. 0925-0455: Grant et al., 2003a; Ruan et al., 2008) in the past. The design and procedures associated with each of these methodological subcomponents will be explicated and discussed within the body of this IRB submission as necessary.

The NESARC-III will be the fourth national survey conducted by NIAAA. The objectives and content areas of the NESARC-III are extremely similar to those of the prior three NIAAA surveys, with the exception of the NESARC-III s provision for collecting saliva samples. Prior NIAAA national surveys included the 1991-1992 National Longitudinal Alcohol Epidemiologic Survey (OMB No. 0930-0151: Grant et al., 1994), the 2001-2002 Wave 1 NESARC (OMB No. 0925-0484: Grant et al., 2003b), and the 2004-2005 Wave 2 NESARC (OMB No. 0925-0484: Grant et al., 2006).
The invention discloses an anti-human PD1 nanometer antibody, a coding sequence, a preparation method and application thereof, and relates to an anti-PD 1 nanometer antibody, wherein the VHH chain of the anti-PD 1 nanometer antibody has an amino acid sequence shown as SEQ ID NO. 2 or SEQ ID NO. 11. Compared with the prior art, the invention has the following advantages: (1) The anti-PD 1 nano antibody has high specificity, high affinity and high detection sensitivity; (2) The antibody can be efficiently expressed in escherichia coli, so that a foundation is provided for subsequent mass production of the immunoreagent and tumor pharmaceutical composition. The invention discloses an anti-human PD1 nanometer antibody, a coding sequence, a preparation method and application thereof, and relates to an anti-PD 1 nanometer antibody, wherein the VHH chain of the anti-PD 1 nanometer antibody has an amino acid sequence shown as SEQ ID NO. 2 or SEQ ID NO. 11. Compared with the prior art, the invention has the following advantages: (1) The anti-PD 1 nano antibody has high specificity, high affinity and high detection sensitivity; (2) The antibody can be efficiently expressed in escherichia coli, so that a foundation is provided for subsequent mass production of the immunoreagent and tumor pharmaceutical composition.
This is a prospective, non-interventional, observational, single-centre, open-label study. Chinese adult (18-65 years old) and adolescent (12-17 years old) HDM AR patients who are newly prescribed with ACARIZAX® at the discretion of attending physician, according to the approved indication by Hainan Provincial Health Commission, will be recruited for this study. Approximately 100 adult (18-65 years old) and adolescent (12-17 years old) patients are expected to be enrolled from Hainan Branch Hospital of Ruijin Hospital. Patients are included in the study only after the decision for treatment with ACARIZAX® has been made, and only with the objective of collecting relevant data about clinical effectiveness and safety of treatment with ACARIZAX® under real-world conditions. No further medical procedures beyond standard care at the discretion of the attending physician are necessary for participation in this study.

Over the 13-month study (including 12-month of treatment), total of 5 scheduled visits will be documented: enrolment and first administration of ACARIZAX® (Visit 1, V0), and subsequent visits performed in 3-month intervals after the first administration at the third month (Visit 2, V1), sixth month (Visit 3, V2), ninth month (Visit 4, V3), and twelfth month (Visit 5, V4) respectively. The actual number and duration of follow-up visits are according to routine practice and may be changed at the physician's discretion. All adverse events (AE) will be collected from the first dose administration until 30 days after the last dose of ACARIZAX® (end of study).
BACKGROUND: Optical atrophy 1 (OPA1), a protein accountable for mitochondrial fusion, facilitates the restoration of mitochondrial structure and function following cerebral ischemia/reperfusion (I/R) injury. The OPA1-conferred mitochondrial protection involves its expression and activity, which can be improved by SIRT3 in non-cerebral ischemia. Nevertheless, it remains obscure whether SIRT3 enhances the expression and activity of OPA1 after cerebral I/R injury.
METHODS: Mature male Sprague Dawley rats were intracranially injected with adeno-associated viral-Sirtuin-3(AAV-SIRT3) and AAV-sh_OPA1, followed by a 90-min temporary blockage of the middle cerebral artery and subsequent restoration of blood flow. Cultured cortical neurons of rats were transfected with LV-SIRT3 or LV-sh_OPA1 before a 2-h oxygen-glucose deprivation and reoxygenation. The rats and neurons were subsequently treated with a selective OPA1 activity inhibitor (MYLS22). The interaction between SIRT3 and OPA1 was assessed by molecular dynamics simulation technology and co-immunoprecipitation. The expression, function, and specific protective mechanism of SIRT3 were examined by various analyses.
RESULTS: SIRT3 interacted with OPA1 in the rat cerebral cortex before and after cerebral I/R. After cerebral I/R damage, SIRT3 upregulation increased the OPA1 expression, which enhanced deacetylation and OPA1 activity, thus alleviating cerebral infarct volume, neuronal apoptosis, oxidative pressure, and impairment in mitochondrial energy production; SIRT3 upregulation also improved neuromotor performance, repaired mitochondrial ultrastructure and membrane composition, and promoted the mitochondrial biogenesis. These neuroprotective effects were partly reversed by OPA1 expression interference and OPA1 activity inhibitor MYLS22.
CONCLUSION: In rats, SIRT3 enhances the expression and activity of OPA1, facilitating the repair of mitochondrial structure and functional recovery following cerebral I/R injury. These findings highlight that regulating SIRT3 may be a promising therapeutic strategy for ischemic stroke.
In the seven-week intervention, the Point-of-Care PCR-testing device will be made available for approximate 50 clinics. Besides the general instructions on how to include patients, clinics in the intervention arm will be instructed that it is entirely up to the GP whether or not to use the PCR-testing device on each individual patient. In addition, no specific instructions on medical treatments or follow up procedures are made.
Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
This essay details the author's personal process of being diagnosed with endometriosis, including her experience of medical gaslighting and societal attitudes toward "period pain." Many people who experience excessive menstrual pain report dismissive attitudes and/or trivialization of their symptoms, from both the public and health professionals. The author recalls conversations from throughout her diagnostic journey, which evidence the ingrained beliefs and attitudes of gendered observations of pain. Ultimately, the author contends that the "burden of proof" is with the patient, being forced to continually fight for their right to be heard in an archaic medical system. The people experiencing this condition are experts-by-experience, who are continually providing knowledge about endometriosis, and self-advocating to rewrite the societal narratives concerning menstrual pain. The goal of this essay is not to blame or cause discomfort, but rather to raise awareness and encourage everyone to talk more openly about menstrual related issues. The following prose is written as a first-person account of my experience with this condition, drawing on appropriate support from academic literature.
Although the patient is sedated and local analgesia has been given, transvaginal oocytes retrieval with ultrasound guidance can still cause a lot of pain, both during and after the procedure. To reduce the pain, some clinics prefer to use needles as thin as 0.8 mm (outer diameter, OD). A disadvantage with these needles is the increased aspiration time. Therefore a new needle has been developed that has the possibility to reduce pain without a large increase in aspiration time. The needle has a 50 mm long tip with an outer diameter of 0.9 mm. The remaining part of the needle is 300 mm long with an outer diameter of 1.4 mm.
Hair and scalp preparations comprise a mixture of a soap or a sulphonated detergent with an organic ester of a phosphoric acid comprising a hydrocarbon radical, having at least 6 carbon atoms, which is linked to the phosphoric acid radical through a di- or polyalkylene oxide group, the pH of the ester having been adjusted to between 6 and 8. Adjuvants of various kinds may be incorporated.  In an example, a shampoo contains a tertiary ester of orthophosphoric acid. with dodecyldiglycol, a mixed ester from 1 mol. dodecyl alcohol, 1 mol. polyglycol (mol. wt. 300) and 1 mol. orthophosphoric acid, the sodium salt of the condensation product of lauric acid chloride with m-amino - phenyl phosphoric acid, and the potassium soap of coconut oil.ALSO:Hair and scalp preparations comprise a mixture of a soap, oil or fat with an organic ester of a phosphoric acid comprising a hydrocarbon radical, having at least 6 carbon atoms, which is linked to the phosphoric acid radical through a di- or polyalkylene oxide group, the pH of the ester having been adjusted to between 6 and 8.  Adjuvants of various kinds may be incorporated. In examples: (1) a hair oil consists of 20 parts of a tertiary ester of orthophosphoric acid with dodecyltetraglycol and 80 parts of liquid paraffin: (2) a hair rinse consists of 30 parts of the sodium salt of the primary ester of orthophosphoric acid with oleyl diglycol, 20 parts liquid paraffin, 10 parts of the polyester of orthophosphoric acid with a polyglycol (mol. wt. 300) and 40 parts water: (3) a shampoo consists of 60 parts of a mixture consisting of 20 parts of a tertiary ester of orthophosphoric acid with dodecyldiglycol, 40 parts of a mixed ester from 1 mol. dodecyl alcohol, 1 mol. polyglycol (mol. wt. 300) and 1 mol. orthophosphoric acid, 40 parts of the sodium salt of the condensation product of lauric acid chloride with m-amino-phenyl phosphoric acid, mixed with 40 parts of potassium soap of coconut oil; (4) a hair rinse consists of 50 parts of the tertiary ester of orthophosphoric acid with dodecyldiglycol.  20 parts of the potassium salt of the secondary ester of orthophosphoric acid with dodecyltetraglycol, 30 parts of a mixture of dodecylglycol and polyglycol esters of orthophosphoric acid and 100 parts paraffin: (5) 100 parts of the mixture as in (4) plus 2 parts of cholesterol phosphate: (6) for destroying lice 80 parts of the mixture as in (4) plus 20 parts of the copper salt of the primary ester of orthophosphoric acid with chlorophenol and preferably with 0.1-0.5 per cent of D.D.T.: (7) a scalp preparation consists of a conventional hair lotion to 100 c.c.s. of which is added 2 gms. 10 per cent olein soap solution and 2 gms. of an ester mixture of 1 mol. orthophosphoric acid with 2 mols. of the octadecyl ether of a polyglycol.
This is an observational study. This study will only recruit Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations. The clinical characteristics, including but not limited to, the degree of change of the motor tapping score, during an "off" period of this group of subjects with severe hypertension. There is a screening visit, a at home monitoring period, and a one-time 4-8 hour study visit for subjects that satisfy the inclusion criteria. The screening visit will assess Parkinson's motor state and review the inclusion/exclusion criteria. The at home monitoring period will measure blood pressure twice a levodopa cycle for 5 cycles (for most subjects, this will be for two days and is dependent on the subject's clinical levodopa cycle). Measurements will occur pre-levodopa dose (the maximal "OFF" time), and half-way through the cycle (maximal "ON" time). The percentage of change will be calculated and those that have a systolic change of greater than or equal to 50% will proceed to the outpatient visit. The outpatient visit will measure blood pressure, pulse, Parkinson's motor symptoms, and plasma levodopa levels.